These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 35567649)

  • 1. Germline sequencing for presumed germline pathogenic variants via tumor-only comprehensive genomic profiling.
    Kondo T; Yamamoto Y; Fukuyama K; Kanai M; Yamada A; Matsubara J; Quy PN; Yoshioka M; Yamada T; Minamiguchi S; Matsumoto S; Kosugi S; Muto M
    Int J Clin Oncol; 2022 Aug; 27(8):1256-1263. PubMed ID: 35567649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Handling of Germline Findings in Clinical Comprehensive Cancer Genomic Profiling.
    Okazawa-Sakai M; Yamamoto Y; Futagawa M; Okamura M; Miyawaki S; Nishina T; Takehara K; Kozuki T; Tomida S; Hyodo I; Ohsumi S; Hirasawa A
    Acta Med Okayama; 2022 Dec; 76(6):673-678. PubMed ID: 36549769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of pathogenic germline variants in the circulating tumor DNA testing.
    Yamamoto Y; Fukuyama K; Kanai M; Kondo T; Yoshioka M; Kou T; Quy PN; Kimura-Tsuchiya R; Yamada T; Matsumoto S; Kosugi S; Muto M
    Int J Clin Oncol; 2022 Oct; 27(10):1554-1561. PubMed ID: 35870019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of patients with presumed germline pathogenic variant from tumor-only genomic sequencing: A retrospective analysis at a single facility.
    Kawamura M; Shirota H; Niihori T; Komine K; Takahashi M; Takahashi S; Miyauchi E; Niizuma H; Kikuchi A; Tada H; Shimada M; Kawamorita N; Kanamori M; Sugiyama I; Tsubata M; Ichikawa H; Yasuda J; Furukawa T; Aoki Y; Ishioka C
    J Hum Genet; 2023 Jun; 68(6):399-408. PubMed ID: 36804482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort.
    Vanni I; Pastorino L; Andreotti V; Comandini D; Fornarini G; Grassi M; Puccini A; Tanda ET; Pastorino A; Martelli V; Mastracci L; Grillo F; Cabiddu F; Guadagno A; Coco S; Allavena E; Barbero F; Bruno W; Dalmasso B; Bellomo SE; Marchiò C; Spagnolo F; Sciallero S; Berrino E; Ghiorzo P
    J Transl Med; 2024 May; 22(1):462. PubMed ID: 38750555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations.
    Kuzbari Z; Bandlamudi C; Loveday C; Garrett A; Mehine M; George A; Hanson H; Snape K; Kulkarni A; Allen S; Jezdic S; Ferrandino R; Westphalen CB; Castro E; Rodon J; Mateo J; Burghel GJ; Berger MF; Mandelker D; Turnbull C
    Ann Oncol; 2023 Mar; 34(3):215-227. PubMed ID: 36529447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of Pathogenic Germline Variants Among Patients With Advanced Colorectal Cancer Undergoing Tumor Genomic Profiling for Precision Medicine.
    You YN; Borras E; Chang K; Price BA; Mork M; Chang GJ; Rodriguez-Bigas MA; Bednarski BK; Meric-Bernstam F; Vilar E
    Dis Colon Rectum; 2019 Apr; 62(4):429-437. PubMed ID: 30730459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenic Germline Variants in BRCA1/2 and p53 Identified by Real-world Comprehensive Cancer Genome Profiling Tests in Asian Patients.
    Satake T; Kondo S; Tanabe N; Mizuno T; Katsuya Y; Sato J; Koyama T; Yoshida T; Hirata M; Yamamoto N
    Cancer Res Commun; 2023 Nov; 3(11):2302-2311. PubMed ID: 37916805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive assessment of germline pathogenic variant detection in tumor-only sequencing.
    Terraf P; Pareja F; Brown DN; Ceyhan-Birsoy O; Misyura M; Rana S; O'Reilly E; Carlo MI; Aghajanian C; Liu Y; Derakhshan F; Jayakumaran G; Weigelt B; Walsh M; Stadler Z; Offit K; Ladanyi M; Robson M; Zehir A; Reis-Filho JS; Mandelker D
    Ann Oncol; 2022 Apr; 33(4):426-433. PubMed ID: 35074424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Utility of Molecular Tumor Board Review for Identification of Possible Germline Pathogenic Variants on Tumor Next-Generation Sequencing Reports.
    Rives TA; Collard J; Li N; Yan D; Dietrich CS; Miller RW; Ueland FR; Pickarski J; Kolesar JM
    JCO Precis Oncol; 2024 Sep; 8():e2400301. PubMed ID: 39259913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current status and issues related to secondary findings in the first public insurance covered tumor genomic profiling in Japan: multi-site questionnaire survey.
    Minamoto A; Yamada T; Shimada S; Kinoshita I; Aoki Y; Oda K; Ueki A; Higashigawa S; Morikawa M; Sato Y; Hirasawa A; Ogawa M; Kondo T; Yoshioka M; Kanai M; Muto M; Kosugi S
    J Hum Genet; 2022 Oct; 67(10):557-563. PubMed ID: 35322199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic landscape of comprehensive genomic profiling in patients with malignant solid tumors in Japan.
    Yamaguchi T; Ikegami M; Aruga T; Kanemasa Y; Horiguchi SI; Kawai K; Takao M; Yamada T; Ishida H
    Int J Clin Oncol; 2024 Oct; 29(10):1417-1431. PubMed ID: 38795236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of actionable germline pathogenic variants identified through tumor next-generation sequencing in a gynecologic cancer cohort.
    Karpel H; Manderski E; Pothuri B
    Int J Gynecol Cancer; 2023 Jul; 33(7):1044-1050. PubMed ID: 36889816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Present status of germline findings in precision medicine for Japanese cancer patients: issues in the current system.
    Higashigawa S; Matsubayashi H; Kiyozumi Y; Kado N; Nishimura S; Oishi T; Sugino T; Fushiki K; Shirasu H; Yasui H; Mamesaya N; Fukuzaki N; Kunitomo K; Horiuchi Y; Kenmotsu H; Serizawa M
    Jpn J Clin Oncol; 2022 May; 52(6):599-608. PubMed ID: 35411369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol.
    Meric-Bernstam F; Brusco L; Daniels M; Wathoo C; Bailey AM; Strong L; Shaw K; Lu K; Qi Y; Zhao H; Lara-Guerra H; Litton J; Arun B; Eterovic AK; Aytac U; Routbort M; Subbiah V; Janku F; Davies MA; Kopetz S; Mendelsohn J; Mills GB; Chen K
    Ann Oncol; 2016 May; 27(5):795-800. PubMed ID: 26787237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current practice of genomic profiling of patients with advanced solid tumours in Italy: the Italian Register of Actionable Mutations (RATIONAL) study.
    Normanno N; De Luca A; Abate RE; Morabito A; Milella M; Tabbò F; Curigliano G; Masini C; Marchetti P; Pruneri G; Guarneri V; Frassineti GL; Fasola G; Adamo V; Daniele B; Berardi R; Feroce F; Maiello E; Pinto C
    Eur J Cancer; 2023 Jul; 187():174-184. PubMed ID: 37167765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of a Collaboration Between a Health Plan, Oncology Practice, and Comprehensive Genomic Profiling Company from the Payer Perspective.
    Reitsma M; Fox J; Borre PV; Cavanaugh M; Chudnovsky Y; Erlich RL; Gribbin TE; Anhorn R
    J Manag Care Spec Pharm; 2019 May; 25(5):601-611. PubMed ID: 30632889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate Cancer.
    Berchuck JE; Boiarsky D; Silver R; Sunkara R; McClure HM; Tsai HK; Siegmund S; Tewari AK; Nowak JA; Lindeman NI; Rana HQ; Choudhury AD; Pomerantz MM; Freedman ML; Van Allen EM; Taplin ME
    JCO Precis Oncol; 2022 Aug; 6():e2200329. PubMed ID: 36103646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group.
    Mandelker D; Donoghue M; Talukdar S; Bandlamudi C; Srinivasan P; Vivek M; Jezdic S; Hanson H; Snape K; Kulkarni A; Hawkes L; Douillard JY; Wallace SE; Rial-Sebbag E; Meric-Bersntam F; George A; Chubb D; Loveday C; Ladanyi M; Berger MF; Taylor BS; Turnbull C
    Ann Oncol; 2019 Aug; 30(8):1221-1231. PubMed ID: 31050713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility and Clinical Utility of Reporting Hereditary Cancer Predisposition Pathogenic Variants Identified in Research Germline Sequencing: A Prospective Interventional Study.
    Hutchcraft ML; Zhang S; Lin N; Pickarski JC; Belcher EA; Wei S; Bocklage T; Miller RW; Villano JL; Cavnar MJ; Kim J; Arnold SM; Ueland FR; Kolesar JM
    JCO Precis Oncol; 2024 Jan; 8():e2300266. PubMed ID: 38295319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.